Kualitas bukti 4.63/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 4/5
- D2 Otoritas sumber
- 5/5
- D3 Aritmetika
- 5/5
- D4 Ketidakpastian
- 4/5
- D5 Cakupan
- 5/5
- D6 Prosa
- 5/5
- D7 Kejujuran persepsi
- 4/5
- D8 Kelengkapan peringatan
- 5/5
≈ Sama mungkinnya dengan
Dipersepsikan
Kanker testis berada dalam kesenjangan persepsi yang aneh. Sebagian besar pria di bawah 35 pernah mendengar frasa itu tetapi tidak dapat menyebutkan satu pun orang yang mengalaminya, dan kampanye pemeriksaan mandiri — di tempat kampanye itu ada — cenderung menghasilkan lebih banyak kecemasan daripada kalibrasi. Penyakit ini secara bersamaan «kanker paling umum pada pria muda» (fakta yang terdengar mengkhawatirkan) dan «sangat dapat diobati» (fakta yang menetralkan kekhawatiran). Efek bersihnya adalah sebagian besar pria muda secara dramatis meremehkan betapa umumnya sambil melebih-lebihkan betapa mematikannya, menghasilkan risiko yang dirasakan yang arahnya salah pada kedua sumbu.
Sumber: intuisi redaksi, bukan hasil survei
Aktual
~9.810 kasus baru per tahun pada pria AS
penduduk AS (laki-laki)
Tampilkan perhitungan
Data SEER (2021-2023) melaporkan risiko seumur hidup sekitar 0,4 % (1 dari 250) untuk pria AS. Ini adalah angka aktuaria yang disesuaikan usia yang mengintegrasikan tingkat insiden khusus usia sepanjang masa hidup penuh, bukan penggabungan tingkat tahunan yang sederhana. Insiden tahunan ~9.810 kasus baru (perkiraan ACS 2026) terhadap ~168 juta pria AS memberikan tingkat tahunan kasar ~0,0000584, tetapi angka seumur hidup SEER lebih disukai karena kanker testis memiliki kurva insiden yang sangat bergantung usia dengan puncak pada 20-34. Tingkat kelangsungan hidup relatif 5 tahun kira-kira 95 %, sehingga probabilitas seumur hidup meninggal karena kanker testis jauh lebih rendah — sekitar 1 dari 5.000.
Catatan: Risiko seumur hidup 0,4 % berlaku untuk semua pria AS sepanjang masa hidup penuh…
Risiko seumur hidup 0,4 % berlaku untuk semua pria AS sepanjang masa hidup penuh. Risiko tidak terdistribusi merata berdasarkan usia: insiden memuncak tajam antara usia 20 dan 34, menjadikan probabilitas bersyarat bagi pria yang saat ini berada dalam jendela itu lebih tinggi daripada yang disarankan angka semua usia. Sebaliknya, pria yang mencapai 45 tanpa diagnosis secara efektif telah melewati jendela risiko tertinggi. Kriptorkidisme (testis yang tidak turun) meningkatkan risiko individu 4-8x; riwayat keluarga kira-kira menggandakannya. Angka 1-dari-250 adalah untuk diagnosis, bukan kematian — risiko kematian seumur hidup ~1 dari 5.000 mencerminkan kelangsungan hidup lima tahun kira-kira 95 % dengan pengobatan modern. Data SEER mungkin sedikit kurang menghitung kasus pada populasi yang tidak berasuransi atau tidak berdokumen.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
Melanoma (UV)
Berapa peluang terkena melanoma dari paparan sinar matahari tanpa pelindung secara teratur?
Pilih penantang
The phrase “most common cancer in young men” does more rhetorical work than statistical work. SEER data puts the lifetime risk of testicular cancer at approximately 0.4% — about 1 in 250 US males — with an estimated 9,810 new cases and 630 deaths in 2026. The incidence peaks sharply between ages 20 and 34, which is why it earns the “most common in young men” label even though the absolute number is small compared to prostate, lung, or colorectal cancer. The American Cancer Society independently confirms the 1-in-250 figure and notes a lifetime mortality risk of roughly 1 in 5,000, reflecting a disease that is both more common than most young men realise and far less lethal than the word “cancer” implies.
The misperception runs in two directions simultaneously. The “cancer” label triggers a severity heuristic that overshoots reality — most people hear “cancer in young men” and picture chemotherapy wards and early death, not the roughly 95% five-year survival rate that modern treatment delivers. At the same time, the base-rate probability of actually developing it is underestimated because the disease is invisible in everyday life: most men diagnosed are treated and return to normal function without public disclosure, and public-health messaging about self-examination has never achieved the penetration of, say, mammography campaigns. The net effect is a risk that is simultaneously overrated on the severity axis and underrated on the frequency axis.
Age-adjusted incidence has risen from 4.71 to 6.22 cases per 100,000 person-years between 1992 and 2021, with Hispanic men’s rates — climbing at roughly 3% a year — overtaking non-Hispanic White men’s by 2021, part of a longer-run narrowing of the incidence gap between lower- and higher-risk groups that a 2025 SEER-registry analysis says is consistent with prior research. The risk factors that matter most at the individual level are cryptorchidism (4-8x elevation), family history (~2x), and prior diagnosis in the contralateral testis. For a man currently in the 20-34 peak window, the conditional annual probability is meaningfully higher than the all-ages rate; for a man who passes 45 without a diagnosis, the residual risk drops sharply. The 1-in-250 lifetime figure is an average across an uneven distribution, and the clinical reality — high curability, concentrated age window, identifiable risk factors — makes this one of the cancers where individual calibration departs most from the population headline.
Fakta terkait
Peluang seorang pria AS terkena kanker testis seumur hidup sekitar ~1 in 250 lifetime (US men). Secara umum tidak umum, tetapi termasuk kanker tersering pada pria usia 15-35 tahun, dan sebagian besar kasus terdeteksi dan berhasil diobati.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
2/3 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] National Cancer Institute — Surveillance, Epidemiology, and End Results (SEER) Program — Cancer Stat Facts: Testicular Cancer Terverifikasi
Cancer Stat Facts: Testicular Cancer- Statistik
Approximately 0.4% of men will be diagnosed with testicular cancer at some point during their lifetime, based on 2021-2023 data- Kutipan
“"Approximately 0.4 percent of men will be diagnosed with testicular cancer at some point during their lifetime, based on 2021–2023 data. The rate of new cases of testicular cancer was 6.1 per 100,000 men per year based on 2019–2023 cases. Testicular cancer is most frequently diagnosed among men aged 20–34." ”
- Data sumber dari
- 2025-01-15
- Diakses
- 2026-04-24 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- SEER's 0.4% lifetime risk is the primary normalized figure. It is derived from age-specific incidence rates applied to the US male life table, making it more accurate than a simple compound of the crude annual rate. The 6.1 per 100,000 age-adjusted annual incidence rate corroborates the native numerator: 6.1 × 1,680 (per 100K males) ≈ 10,248, consistent with the ACS 2026 estimate of 9,810 new cases.
-
[2] American Cancer Society — Key Statistics for Testicular Cancer
Key Statistics for Testicular Cancer- Statistik
About 9,810 new cases and 630 deaths estimated for 2026; about 1 in 250 males will develop testicular cancer in their lifetime- Kutipan
“"The American Cancer Society's estimates for testicular cancer in the United States for 2026 are: About 9,810 new cases of testicular cancer diagnosed. About 630 deaths from testicular cancer. Testicular cancer is not common: about 1 of every 250 males will develop testicular cancer at some point during their lifetime. The average age at the time of diagnosis of testicular cancer is about 33. Because testicular cancer usually can be treated successfully, a man's lifetime risk of dying from this cancer is very low: about 1 in 5,000." ”
- Data sumber dari
- 2026-01-01
- Diakses
- 2026-04-24 · salinan arsip
- Perhitungan
- ACS independently confirms the 1-in-250 lifetime risk and provides the 2026 case/death estimates. The 1-in-5,000 lifetime mortality risk implies a case-fatality ratio of roughly 6.4% over the full disease course (250/5000), consistent with the roughly 95% 5-year survival reported by SEER. Used here as corroboration of both the incidence and the high-survivability framing.
-
[3] Cancer (Almeida et al. 2025, American Cancer Society journal, Wiley) — Racial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992-2021 Terverifikasi
Racial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992-2021- Statistik
Age-standardized testicular germ cell tumor incidence rose from 4.71 to 6.22 per 100,000 person-years between 1992 and 2021 (overall AAPC 1992-2021: 0.92%); incidence among Hispanic men rose fastest (AAPC 3.03%) and surpassed the non-Hispanic White rate by 2021- Kutipan
“"Incidence among Hispanic men more than doubled from 1992 to 2021 (1992 [ASR per 100,000 person-years, 3.22; 95% CI, 2.60–4.01] vs. 2021 [ASR per 100,000 person-years, 7.58; 95% CI, 6.88–8.34]), surpassing rates among NHW men by 2021." ”
- Data sumber dari
- 2025-01-06
- Diakses
- 2026-07-04 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- SEER-12-registry analysis of testicular germ cell tumor incidence trends, 1992-2021, published in Cancer (Almeida et al., Jan 2025). Supports the body text's claim of rising incidence with a precise figure (4.71 to 6.22 cases per 100,000 person-years) and documents that Hispanic men's incidence, climbing at an average annual percent change of 3.03%, overtook the non-Hispanic White rate by 2021 -- the convergence referenced in the body text. Not used for the headline lifetime-risk (0.4%) or 2026 case/death estimates, which come from SEER Stat Facts and the American Cancer Society sources above.
- Independensi
- Independent SEER-registry academic analysis (NCI-affiliated authors), distinct from the SEER Stat Facts summary page and the ACS key-statistics page already cited above.